Amneal Pharmaceuticals has just seen its fair value estimate nudged to US$14.00 from US$13.80, a small but meaningful reset that ties directly to how the latest quarterly numbers stack up against ...

Biosimilar partnerships and EU approvals surge, enhancing access to innovative treatments in immunology, oncology, and bone ...

Denosumab is a monoclonal antibody that inhibits bone resorption and is widely used across oncology and osteoporosis-related ...